P2, N=26, Completed, Henan Cancer Hospital | Recruiting --> Completed | N=60 --> 26 | Trial completion date: Apr 2025 --> Mar 2026 | Trial primary completion date: Dec 2023 --> Jul 2025

13 days ago

Trial completion • Enrollment change • Trial completion date • Trial primary completion date

Rituxan (rituximab) • bortezomib • cyclophosphamide • epirubicin • prednisone

14d

Effective Management of Chemotherapy-Induced Cardiotoxicity: A Prospective Follow-Up Study on Alternative Regimens in Bangladeshi Cancer Patients. (PubMed, Cureus)

Initial regimens included doxorubicin (42%), epirubicin (18%), taxanes (paclitaxel/docetaxel/nab-paclitaxel; 25%), and fluoropyrimidines (5-fluorouracil/capecitabine; 15%), all discontinued due to toxicity. Patients were switched to liposomal doxorubicin (n=73) or non-anthracycline protocols (e.g., gemcitabine-based; n=39)...In resource-limited settings like Bangladesh, prioritizing liposomal formulations for high-risk patients could mitigate cardiotoxicity burdens. Integrated cardio-oncology protocols are recommended.

14 days ago

Journal

NPPB (Natriuretic Peptide B)

gemcitabine • 5-fluorouracil • capecitabine • albumin-bound paclitaxel • epirubicin

14d

A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer (clinicaltrials.gov)

P3, N=1800, Recruiting, Shanghai JMT-Bio Inc. | Not yet recruiting --> Recruiting

14 days ago

Enrollment open

HER-2 (Human epidermal growth factor receptor 2)

HER-2 positive

Herceptin (trastuzumab) • carboplatin • docetaxel • Perjeta (pertuzumab) • doxorubicin hydrochloride • cyclophosphamide • epirubicin • anbenitamab (KN026)

20d

NeoSACT: The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC (clinicaltrials.gov)

P2, N=29, Completed, Guangdong Provincial People's Hospital | Active, not recruiting --> Completed

20 days ago

Trial completion

carboplatin • Focus V (anlotinib) • Tyvyt (sintilimab) • albumin-bound paclitaxel • cyclophosphamide • epirubicin

29d

BRCA2 Reversion Mutation after Neoadjuvant Dose-Dense EC and Dose-Dense Paclitaxel in Triple-Negative Breast Cancer: A Case Report and Literature Review. (PubMed, Surg Case Rep)

This case suggests that a BRCA2 reversion mutation can arise early, even before PARPi or platinum exposure. Serial monitoring of BRCA status may help predict therapeutic resistance in patients with germline BRCA-mutated breast cancer.

29 days ago

Journal • BRCA Biomarker • PARP Biomarker

BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)

BRCA2 mutation • BRCA mutation

paclitaxel • cyclophosphamide • epirubicin

29d

Biomimic colloidal self-assembly of epirubicin/ferric ion multi-enzyme delivery for synergistic photothermal therapy of metastatic triple-negative breast cancer. (PubMed, Colloids Surf B Biointerfaces)

PEF NDs had no detrimental effects on vital organs (heart, kidney, liver, lung, or spleen), indicating acceptable in vivo biosafety. Self-assembled nanodrugs with simultaneous photothermal and anti-inflammatory properties have considerable clinical potential in the treatment of metastatic malignancies.

29 days ago

Journal

MMP9 (Matrix metallopeptidase 9) • CAT (Catalase)

epirubicin

29d

OPTIMA-YOUNG: Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests (clinicaltrials.gov)

P3, N=3380, Not yet recruiting, UNICANCER

29 days ago

Trial initiation date

HER-2 (Human epidermal growth factor receptor 2)

HR positive • HER-2 amplification • HER-2 negative • HER-2 expression

Prosigna™ Breast Cancer Prognostic Gene Signature Assay

paclitaxel • docetaxel • tamoxifen • doxorubicin hydrochloride • cyclophosphamide • letrozole • epirubicin • anastrozole • exemestane • triptorelin • goserelin acetate • leuprolide acetate for depot suspension

29d

A Single-Arm, Single-Center, Phase II Clinical Study of Camrelizumab Combined With Radiochemotherapy as Neoadjuvant Therapy for Early-Stage Triple-Negative Breast Cancer (clinicaltrials.gov)

P=N/A, N=43, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital

29 days ago

New trial

HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)

HER-2 negative • ER negative

carboplatin • AiRuiKa (camrelizumab) • albumin-bound paclitaxel • cyclophosphamide • epirubicin

LESLIE: LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer (clinicaltrials.gov)

P2, N=356, Recruiting, Universitaire Ziekenhuizen KU Leuven | Not yet recruiting --> Recruiting | Trial completion date: Mar 2031 --> Sep 2031 | Trial primary completion date: Mar 2028 --> Sep 2028

1 month ago

Enrollment open • Trial completion date • Trial primary completion date

HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)

Keytruda (pembrolizumab) • carboplatin • paclitaxel • cyclophosphamide • epirubicin

Refining Risk Assessment for Adjuvant CDK4/6 Inhibitors beyond Trial Inclusion Criteria: Integrating Recurrence Score and Endocrine Responsiveness according to ADAPT. (PubMed, Breast Care (Basel))

Patients with c/pN2-3 or G3 with Ki67 >40% were randomized directly to CTx subtrial evaluating (neo)adjuvant paclitaxel vs. nab-paclitaxel, followed by epirubicin + cyclophosphamide and ET...Assuming a hazard ratio of 0.7 for a ribociclib effect in NATALEE, an absolute benefit of approximately 2% fewer dDFS events after 5 years could be expected in this group based on the WSG-ADAPT-HR+/HER2- experience. ET-response evaluation can refine prognosis to better inform shared decision-making in this intermediate-risk group.

1 month ago

Journal

HER-2 (Human epidermal growth factor receptor 2)

HER-2 negative

Verzenio (abemaciclib) • albumin-bound paclitaxel • cyclophosphamide • Kisqali (ribociclib) • epirubicin